Latigo Raises $346M in IPO to Push Its Non-Opioid Painkillers Toward Market

Latigo Biotherapeutics raised $346 million in an initial public offering to advance a pipeline of non-opioid painkillers — a hot area as the industry seeks alternatives to addictive opioids.

The company priced 19.2 million shares at $18 — the top of its range — on August 9, 2026, and trades on the Nasdaq as LTGO.

The target

Lead drug LTG-001 is a selective inhibitor of Nav1.8, a sodium channel in peripheral nerves that carries pain signals. It is designed to relieve pain without acting on the brain the way opioids do.

The choice of channel is what makes the approach viable. Sodium channels generate the electrical impulses all nerves use, so blocking them indiscriminately — which is what local anaesthetics do — stops every kind of nerve signalling, including movement and sensation generally. That is acceptable locally and impossible systemically.

Nav1.8 is different because it is expressed almost exclusively in pain-sensing neurons outside the brain and spinal cord. A drug selective for it therefore interrupts pain signalling specifically, leaves other nerve function intact, and does not reach the brain circuits where opioids produce euphoria and dependence.

Why non-addictive follows from the mechanism

Opioid addiction is not a side effect that could be engineered away while preserving how the drugs work. Opioids relieve pain by acting on receptors in the brain and spinal cord, and those same receptors mediate reward. The analgesia and the addiction potential arise from the same action at the same sites.

Blocking a peripheral channel avoids the problem by never engaging the reward system at all — which is why peripheral targets have been pursued for so long, and why they are difficult: pain signalling in the periphery is redundant, so blocking one channel may not be sufficient for severe pain.

The efficacy claim

In earlier Phase 2b testing, LTG-001 delivered meaningful pain relief in 52 minutes, versus 83 minutes for an opioid comparator. The company aims to outperform Vertex’s Journavx, the first drug in the class, approved in 2025.

Speed of onset is a genuine differentiator in acute pain — someone after surgery or injury needs relief promptly, and a half-hour difference is clinically noticeable.

It is also a narrower claim than superior pain relief. Onset speed says nothing about how much pain is relieved or for how long, and the comparison that will ultimately matter is against Journavx rather than against an opioid.

The rest of the pipeline

Latigo is also developing LTG-321, a next-generation Nav1.8 inhibitor in Phase 2 for osteoarthritis with data expected in the second half of 2027, and an earlier programme, LTG-418.

The osteoarthritis programme addresses a different and harder problem. Acute pain is short-lived and its cause resolves; chronic pain involves changes in how the nervous system processes signals, and peripheral blockade has historically worked less well against it.

The commercial prize is correspondingly larger. Osteoarthritis affects an enormous population currently managed with NSAIDs that carry gastrointestinal and cardiovascular risks with long-term use, and a safe alternative for daily chronic use would be worth considerably more than an acute-pain product.

The money and the window

Latigo budgeted about $124.7 million to take LTG-001 through a Phase 3 readout, with cash runway into the second quarter of 2028.

How long this target took to reach

Nav1.8 has been a recognised pain target for decades, and the delay in producing a drug illustrates why the approval of the first one was notable.

The difficulty is selectivity. Human cells express several closely related sodium channel subtypes with similar structures, some of which are essential to heart rhythm and to nerve function generally. A compound blocking Nav1.8 must therefore leave near-identical proteins untouched, and achieving that discrimination chemically defeated many programmes.

Insufficient selectivity produces cardiac or neurological toxicity, and several earlier candidates across the industry failed for exactly that reason. The first approval in 2025 demonstrated the problem was solvable, which is a significant part of why capital has flowed to competitors since.

The market the class is entering

Acute pain after surgery or injury is currently managed with opioids, NSAIDs and paracetamol, and the gap a non-opioid would fill is specific.

NSAIDs and paracetamol handle mild to moderate pain adequately but are insufficient for severe pain. Opioids handle severe pain and carry dependence risk, respiratory depression and the prescribing scrutiny that followed the opioid crisis — which has made clinicians reluctant to prescribe them even where they are appropriate.

That reluctance created a real problem of undertreated pain. A drug offering opioid-level relief without addiction risk would resolve a genuine clinical bind, and the commercial question is whether the class delivers enough analgesia for severe pain or whether it settles into the middle ground NSAIDs already occupy.

It was not alone: cancer-drug developer BlossomHill Therapeutics debuted in the same stretch, raising $150 million. The back-to-back offerings underscore renewed investor appetite for biotech — and, for Latigo, real money to test whether a non-opioid can carve share in pain treatment. Business news, not investment advice.